Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01360086
Other study ID # CDR0000699219
Secondary ID FFCD-0901EU-2111
Status Completed
Phase Phase 2
First received May 20, 2011
Last updated May 27, 2016
Start date June 2011
Est. completion date March 2013

Study information

Verified date May 2016
Source Federation Francophone de Cancerologie Digestive
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving more than one drug (combination chemotherapy) together with cetuximab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these drugs after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying the side effects of giving fluorouracil, cisplatin, and leucovorin calcium together with cetuximab and to see how well they work in treating patients with adenocarcinoma of the stomach or gastroesophageal junction.


Description:

OBJECTIVES:

Primary

- To evaluate the objective response rate according to RECIST V1.1 criteria in patients with adenocarcinoma of the stomach or gastroesophageal junction treated with neoadjuvant chemotherapy comprising fluorouracil, cisplatin, leucovorin calcium, and cetuximab followed by surgery and adjuvant chemotherapy.

- To determine the non-toxicity rate in these patients.

Secondary

- To determine the rate of macroscopically and microscopically complete surgical resection (R0).

- To determine the overall tolerance in patients treated with this regimen.

- To determine post-operative mortality and morbidity in these patients.

- To determine the rate of recurrence at 1 and 2 years in these patients.

- To determine recurrence-free survival at 3 years in these patients.

- To determine disease-free survival at 3 years in these patients.

- To determine overall survival at 3 years in these patients.

- To determine quality of life using EORTC QLC-C30 and STO-22 questionnaires.

- To determine the correlation between the response rate and the degree of skin toxicity.

OUTLINE: This is a multicenter study.

- Neoadjuvant therapy and surgery: Patients receive leucovorin calcium IV over 2 hours, cisplatin IV, fluorouracil IV continuously over 46 hours, and cetuximab IV over 1-2 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks after completing neoadjuvant chemotherapy, patients undergo surgery.

- Adjuvant therapy: Within 4-8 weeks after completing neoadjuvant chemotherapy, patients receive leucovorin calcium, cisplatin, fluorouracil, and cetuximab as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients complete quality-of-life questionnaires (QLC-C30 and STO-22) periodically. Blood and tissue samples are collected periodically for correlative and translational studies.

After completing study therapy, patients are followed up every 4 months for 2 years and then every 6 months for 1 year.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date March 2013
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction

- Stage IB, II, or III disease according to TNM classification OR type I, II, or III disease according to Siewert classification

- TNM: T1N1-3, T2N0-3, T3N0-3, or T4N0-3 (no T1N0 or M1)

- Disease considered operable with curative intent

- No gastric scirrhous carcinoma (linitis plastica)

- Forms with independent cells are not considered linitis

- Measurable disease according to RECIST V1.1

- No planned esophagectomy without thoracotomy in patients with adenocarcinoma of the gastroesophageal junction type I

PATIENT CHARACTERISTICS:

- WHO performance status 0-2

- Polynuclear neutrophil count = 1,500/mm³

- Platelet count = 100,000/mm³

- Creatinine clearance > 50 mL/min

- Bilirubin < 1.5 times normal

- Serum albumin > 30 g/L

- Prothrombin time = 80%

- FEV1 > 1 L in case of thoracotomy

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No known cirrhosis

- No other progressive condition that has not been stabilized including the following:

- Hepatic failure

- Renal failure

- Respiratory failure

- NYHA class III-IV congestive heart failure

- Unstable angina

- Myocardial infarction in the past 6 months

- Significant arrhythmias in the past 12 months

- No recent weight loss exceeding 15%

- No interstitial pneumonia

- No other malignant tumor within the past 5 years except for basal cell skin carcinoma or cancer in situ of the cervix

- No psychological, familial, or geographical reasons that will preclude the patient being monitored regularly

- No persons deprived of liberty or under guardianship (Disability Act)

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior chemotherapy or radiotherapy for gastric cancer

- No other concurrent anticancer treatment, immunotherapy, or hormone therapy

- No prior abdominal or thoracic radiotherapy

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
cetuximab
6 cycles of intravenous Cetuximab (500mg/m²),
Drug:
cisplatin
Cisplatine (50mg/m²)
fluorouracil
LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
leucovorin calcium

Procedure:
adjuvant therapy

neoadjuvant therapy

quality-of-life assessment

therapeutic conventional surgery
Surgery was planned 3-4 weeks after the end of neaodjuvant CT

Locations

Country Name City State
France Centre Hospitalier Regional et Universitaire de Lille Lille
France CHU - Robert Debre Reims

Sponsors (1)

Lead Sponsor Collaborator
Federation Francophone de Cancerologie Digestive

Country where clinical trial is conducted

France, 

References & Publications (1)

Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, Bosset JF, Mabrut JY, Triboulet JP, Bedenne L, Seitz JF. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal can — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate according to RECIST V1.1 criteria 3 months No
Primary Non-toxicity rate 3 months Yes
Secondary Tolerance From Inclusion Yes
Secondary Post-operative mortality and morbidity After Surgery Yes
Secondary Rate of recurrence at 1 and 2 years 1 year and 2 years No
Secondary Recurrence-free survival at 3 years 3 years No
Secondary Disease-free survival at 3 years 3 years No
Secondary Overall survival at 3 years 3 years No
Secondary Quality of life as assessed by QLC-C30 and STO-22 questionnaires From inclusion No
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2